Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$27,000.00

Investigating how Signal Transducer and Activator of Transcription 5B promotes chemotherapy-resistance in T-cell acute lymphoblastic leukemia

EF 2024-25

Résumé
Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children, with a subtype called T-cell ALL (T-ALL) making up 25% of pediatric and 15% of adult cases. Current treatments for T-ALL involve intense chemotherapy, which often causes serious long-term side effects, particularly for children. Worse still, 20% of children and 60% of adults with T-ALL do not respond to treatment, leading to very poor survival rates. This makes it important to understand why some T-ALL patients dont respond to therapy.T-ALL starts when blood stem cells develop mutations, turning into pre-leukemic stem cells (preLSCs) and leukemia stem cells (LSCs), which lead to the uncontrolled production of abnormal T-cells. These preLSCs and LSCs often survive chemotherapy and may be responsible for relapse, however, how they resist therapy it is not fully understood. A gene called LMO2 plays a key role in about 50% of T-ALL cases. Of those 50%, STAT5B is involved in cell growth and survival and is found to be active. STAT5B helps preLSCs and LSCs resist chemotherapy, making it an important target for new treatments. However, blocking STAT5B in patients is challenging because it also plays a role in normal blood cell production.Our research aims to understand how STAT5B helps T-ALL cells survive and resist treatment. We will use a combination of genetic and drug-testing approaches in mouse models and patient-derived cells to uncover how STAT5B works in acute leukemia. By identifying the specific processes that allow T-ALL to evade therapy, we hope to develop more precise treatments that reduce the chances of relapse and lower the harmful side effects of chemotherapy.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529789
Name
Lucas Johnathon T
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating how Signal Transducer and Activator of Transcription 5B promotes chemotherapy-resistance in T-cell acute lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Leukemia; Blood; Cancer; Childhood Cancer; Leukemia; Stat5; Stem Cells; T-Cells; Targeted Therapies; Therapy-Resistance
Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children, with a subtype called T-cell ALL (T-ALL) making up 25% of pediatric and 15% of adult cases. Current treatments for T-ALL involve intense chemotherapy, which often causes serious long-term side effects, particularly for children. Worse still, 20% of children and 60% of adults with T-ALL do not respond to treatment, leading to very poor survival rates. This makes it important to understand why some T-ALL patients dont respond to therapy.T-ALL starts when blood stem cells develop mutations, turning into pre-leukemic stem cells (preLSCs) and leukemia stem cells (LSCs), which lead to the uncontrolled production of abnormal T-cells. These preLSCs and LSCs often survive chemotherapy and may be responsible for relapse, however, how they resist therapy it is not fully understood. A gene called LMO2 plays a key role in about 50% of T-ALL cases. Of those 50%, STAT5B is involved in cell growth and survival and is found to be active. STAT5B helps preLSCs and LSCs resist chemotherapy, making it an important target for new treatments. However, blocking STAT5B in patients is challenging because it also plays a role in normal blood cell production.Our research aims to understand how STAT5B helps T-ALL cells survive and resist treatment. We will use a combination of genetic and drug-testing approaches in mouse models and patient-derived cells to uncover how STAT5B works in acute leukemia. By identifying the specific processes that allow T-ALL to evade therapy, we hope to develop more precise treatments that reduce the chances of relapse and lower the harmful side effects of chemotherapy.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lucas, Johnathon T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~